2252493-33-5
2252493-33-5 structure
- Name: (R)-ND-336
- Chemical Name: (R)-ND-336
- CAS Number: 2252493-33-5
- Molecular Formula: C16H18ClNO3S2
- Molecular Weight: 371.90
- Catalog: Signaling Pathways Metabolic Enzyme/Protease MMP
- Create Date: 2020-08-09 11:46:23
- Modify Date: 2024-01-08 17:06:12
-
(R)-ND-336 is a potent and selective MMP-9 inhibitor with a Ki of 19 nM. (R)-ND-336 inhibits MMP-2 (Ki=127 nM) and MMP-14 (Ki=119 nM). (R)-ND-336 has the potential for diabetic foot ulcers (DFUs) research[1].
| Name | (R)-ND-336 |
|---|
| Description | (R)-ND-336 is a potent and selective MMP-9 inhibitor with a Ki of 19 nM. (R)-ND-336 inhibits MMP-2 (Ki=127 nM) and MMP-14 (Ki=119 nM). (R)-ND-336 has the potential for diabetic foot ulcers (DFUs) research[1]. |
|---|---|
| Related Catalog | |
| Target |
MMP-9:19 nM (Ki) MMP-2:127 nM (Ki) MMP-14:119 nM (Ki) |
| In Vitro | (R)-ND-336 poorly inhibits other MMPs (Ki>100 μM). (R)-ND-336 has a long residence time (the time the inhibitor is bound to MMP-9, calculated as 1/koff) of 300 min[1]. A favorable IC50value of 143 μM afforded a therapeutic index (IC50/Ki for MMP-9) ratio of 7530, indicating that (R)-ND-336 is not cytotoxic[1]. |
| In Vivo | (R)-ND-336 (50 μg/wound/day for 14 days) accelerates wound healing faster[1]. (R)-ND-336 has an AUC of 1.3 μM•min after topical administration and 35 μM•min following intravenous dosing, for an AUCtop/AUCiv ratio of 3.7%, indicating minimal absorption after topical administration in db/db mice[1]. Animal Model: Female db/db mice (BKS.Cg-Dock7m+/+Leprdb/J, 8-weeks old, ∼40 g body weight)[1] Dosage: 50 μg Administration: Wound; once a day for 14 days Result: Accelerated wound healing faster and showed complete inhibition of MMP-9. |
| References |
| Molecular Formula | C16H18ClNO3S2 |
|---|---|
| Molecular Weight | 371.90 |